Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have a...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!